Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

14.02
-0.3400-2.37%
Post-market: 14.090.0700+0.50%17:24 EDT
Volume:1.23M
Turnover:17.47M
Market Cap:1.80B
PE:-19.05
High:14.93
Open:14.80
Low:14.02
Close:14.36
52wk High:21.50
52wk Low:9.61
Shares:128.30M
Float Shares:78.65M
Volume Ratio:5.93
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7359
EPS(LYR):-0.8457
ROE:-18.22%
ROA:-6.16%
PB:3.13
PE(LYR):-16.58

Loading ...

Mesoblast Trims Option Overhang After Late-2025 Lapse of 1.45 Million Unquoted Options

TIPRANKS
·
Jan 16

Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies

MT Newswires Live
·
Jan 14

Mesoblast Issues 6.9 Million New Shares Following Conversion of Unquoted Securities

TIPRANKS
·
Jan 13

Mesoblast Seeks ASX Quotation for 7.3 Million New Shares from Employee Scheme

TIPRANKS
·
Jan 13

Mesoblast Director Lyn Cobley Increases On-Market Shareholding

TIPRANKS
·
Jan 12

Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales

Benzinga_recent_news
·
Jan 10

Mesoblast Says US Revenue From Sale of Cell Therapy Rises Quarter-on-Quarter in December 2025 Quarter

MT Newswires Live
·
Jan 09

Mesoblast Boosts Ryoncil Sales 60% and Secures Cheaper US$125m Financing

TIPRANKS
·
Jan 09

Mesoblast Ltd - Ryoncil Sales for Quarter Increase 60% to US$35.1M

THOMSON REUTERS
·
Jan 09

Mesoblast Says Chair to Retire, Successor Appointed; Shares Up 3%

MT Newswires Live
·
Jan 02

BRIEF-Mesoblast Appoints Philip Facchina As Non-Executive Chair

Reuters
·
Jan 02

Press Release: Mesoblast Announces Changes to Board of Directors' Leadership Roles

Dow Jones
·
Jan 02

Mesoblast Ltd - Philip Facchina Appointed as Non-Executive Chair

THOMSON REUTERS
·
Jan 02

Mesoblast Ltd - Jane Bell Retires as Chair

THOMSON REUTERS
·
Jan 02

Mesoblast Ltd Files for Offering of Upto $250 Mln Ads Representing Ordinary Shares - SEC Filing

THOMSON REUTERS
·
Dec 31, 2025

Mesoblast to Release 10.2 Million Shares From Voluntary Escrow

MT Newswires Live
·
Dec 30, 2025

Press Release: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Dow Jones
·
Dec 30, 2025

Mesoblast Repays Existing Senior Loans From Shareholder's New Five-Year Facility; Shares Rise 3%

MT Newswires Live
·
Dec 30, 2025

Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?

Simply Wall St.
·
Dec 17, 2025

Mesoblast Says Drug Candidate for Treatment of Severe Acute Graft Versus Host Disease Shows Superior Outcomes Than Ruxolitinib

MT Newswires Live
·
Dec 12, 2025